News Hub | News Direct

Phase 4 Services Adds Marketing and Technology Pro to Broaden Consulting Scope, Better Assist Lab Clients

Phase 4 Services

MCR Labs Director of Marketing & IT Yasha Kahn has been named vice president of marketing & technology at Phase 4 Services, a laboratory management and consulting firm positioned to help hemp and cannabis testing labs capture market share in the expanding cannabis industry. Kahn, an information technology expert with nearly a decade of experience guiding marketing strategy and upgrading IT systems for cannabis testing providers, will be tasked with helping Phase 4 clients secure their data and generate brand awareness. His combined marketing and technology expertise make Kahn uniquely well-suited to offer insights tailored to finding success in the digital age. “As a scientist, promoting the business and managing our data were details I hadn’t really considered when we first opened the lab,” said Michael Kahn, Founder and CEO of MCR Labs, a cannabis testing lab operating in several Northeast cannabis markets. “As the industry here grew, Yasha made sure any potential clients coming in knew our name, and he scaled our technology infrastructure to handle the team’s rapid growth.” In his role at Phase 4 Services, Yasha Kahn will guide the firm’s laboratory partners on decisions related to data security and networking, events and outreach projects, and media strategy both digital and traditional. By adding high-level technology and marketing knowledge to their consulting scope, Phase 4 Services enables their client laboratories to focus on the important work of accurately analyzing cannabis products while helping to bring in new business and ensure the right tools are in place to facilitate operations across departments. About Phase 4 Services: Phase 4 Services is a scientific consulting and laboratory management firm dedicated to growing, supporting, and enhancing hemp and cannabis testing laboratories. Founded by experts in analytical testing, pharmaceutical chemistry, business administration, and development strategy, our team is equipped with the knowledge and experience necessary to ensure partner laboratories are successful in their pursuit of advancing public health and safety for cannabis patients and consumers. For more information visit http://phase4services.com. Contact Details Phase 4 Services Joe Crinkley +1 857-230-0839 PR@phase4services.com Company Website https://phase4services.com/

September 20, 2021 11:11 AM Eastern Daylight Time

WIN Adopts New Corporate Name, Centerboard – The Logistics Industry's Neutral Technology Platform

Centerboard

Leading logistics technology platform, Web Integrated Network (WIN), today announced it will be adopting a new corporate brand name, Centerboard, to best reflect its overall mission of giving shippers control over their supply chain using the growing slate of neutral, shipper-centric transportation and supply chain management technology solutions it is developing. A truly neutral solution, Centerboard empowers the shipper to utilize its own contract carrier relationships – as well as accessing any carrier/broker in the spot market. There is more than $1 billion in freight value running through the platform. The company also unveiled a range of new features for its core platform, now known as WIN, by Centerboard. Centerboard, which will continue to operate as a standalone entity from its former parent company, Odyssey Logistics & Technology Corporation, is focused on providing shippers with solutions that are easy to use, customizable and designed for integration, while being more affordable than other options. Centerboard’s proprietary technologies provide supply chain stakeholders access to real-time data, providing unprecedented transparency and efficiency and helping shippers move goods in the fastest, most cost-effective and sustainable manner. Unlike older legacy systems, the company’s product development approach leverages modern, nimble, modular architecture, enabling Centerboard to offer shippers of all sizes the advantage of continuous improvement with the latest technology. Centerboard’s philosophy and modular approach enables supply chain participants the ability to integrate and upgrade while minimizing development costs. Centerboard’s leadership team consists of Glenn Riggs, President; Lindsey Shellman, Chief Commercial Officer; and Xavier Amella, Chief Technology Officer. The company was founded in 2017 and the cost-effective, cloud-based solutions it created like WIN, by Centerboard have helped companies of all sizes save time and money, resulting in increased profits. “Dairyland Trading Co. is a satisfied customer of WIN. Last year alone the WIN software contributed to our 27 percent year over year growth,” said Jerry Haines, Owner and Manager at Dairyland Trading Co. LLC. “We are looking forward to using the expanded features of the WIN, by Centerboard offering to increase our efficiencies as we continue to meet the shifting demands of shipping our goods.” Centerboard enables shippers to transact with quality carriers as well as successfully and easily integrate with legacy and emerging technology. Along with a new vision for the industry, the rollout comes with new platform features like advanced shipment notifications which sends notifications on all order tracking messages, helping to improve costs, accuracy and flexibility. Additionally, a new spot quote carrier setup feature helps to increase efficiencies. “Working with Centerboard allows us to provide our customers with seamless, easy access to key transportation management features right within our system,” said John Walker, Logistics Product Manager at Encompass Technologies, a comprehensive cloud-based ERP for the beverage and food industry. “Centerboard’s technology architecture is designed to be flexible, modular, and agile, which allows our team to upgrade to the latest technology, saving our team and customers time and money.” “The rollout of Centerboard’s solutions, including our ability to offer both standard and custom integrations, allows us to solve key issues facing the shipping and logistics industry. For the first time, shippers are able to take command of their supply chain and to access the features they need most,” said Glenn Riggs, President of Centerboard. “Supply chain is the lifeblood of business, but it’s complex, fragmented and often difficult to find answers to inform good decision making. Centerboard changes that with simplicity, easy integration capabilities and affordability.” To learn more about Centerboard and the new solutions offered through WIN, by Centerboard, visit www.centerboard.com. About Centerboard Centerboard is a neutral, shipper-centric transportation and supply chain management platform supplying shippers with access to a wide range of affordable features needed to take control of operations. Centerboard unlocks business opportunities for shippers, carriers and supply chain stakeholders, through leveraging real-time data. Centerboard is out to make the supply chain more sustainable and efficient to ensure less waste and significant carbon reduction with every trip. Contact Details Kite Hill PR for Centerboard Kite Hill PR centerboard@kitehillpr.com Company Website https://www.centerboard.com/

September 20, 2021 09:00 AM Eastern Daylight Time

Israeli SleepX to be merged into AppYea Inc. (APYP)

Appyea

AppYea continues the process of merging SleepX into the company. The merger is expected to be completed by 12/01/2021 in accordance with the model published on 08/02/2021 ( Link ) In parallel, SleepX continues developing and improving its algorithms and planning to start production during 2022. The SleepX product is being designed to provide a unique answer to approximately 90 million Americans who suffer from the problem of snoring. DreamIT The night wrist band will include several sensors and a vibration motor which will operates with an intensity adapted to the user's reactions in real time in order to accustom the user to sleep in the correct position using biofeedback, thereby reducing or eliminating snoring. SleepX solution is being developed in collaboration with the Biomedical department of Ben Gurion University in Beer Sheva, and is patent - protected in the US, EU and Israel. https://www.sleepxclear.com/ipportfolio In addition to reducing snoring and improving sleep quality, users will be able to access important statistics relating to their sleep patterns via an app (Apple and Android) to track over time and detect anomalies. Product Clip The sleep apnea market is projected to reach USD 9.9 billion by 2026, at a CAGR of 6.9% during the forecast period. Major factors driving the growth of this market include the growing awareness regarding the detrimental effects of snoring, availability, and benefits of anti-snoring treatments, growing geriatric and obese population, presence of a large number of cigarette smokers and alcoholics, and a large pool of an untapped snoring population. However, poor efficacy of current anti-snoring treatments available in the market, high cost of some of the anti-snoring treatments, and lack of reimbursement are major factors restraining the growth of this market. “The SleepX approach should not only solve physiological problems for a great many people, but it may also allow many couples to go back to sleeping together," says Bary Molchadsky, SleepX's entrepreneur and CEO. “The decision to merge with AppYea was made in order to accelerate the start point of production. Lately, we see major players entering the market – Google presented its new Fitbit watch with the possibility to monitor snoring. Amazon presented at the beginning of the year the new Alexa that is supposed to identify sleep apnea. However, we believe that the patent-protected technology underlying the SleepX approach should be accepted in the marketplace.” “The SleepX products are being designed to provide, besides monitoring, biofeedback based individual treatment, adjusted to each user in real-time. Following the launch of the first snoring treatment product, the company intends to start clinical trials in order to receive FDA approval for sleep apnea treatment.” “I’m certain that tens of thousands of academic research hours together with international strong patents, would provide Appyea’s investors a significant advantage over time.” Legal Notice Regarding Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended. Contact Details Asaf Porat info@appyea.com Company Website http://www.appyea.com

September 17, 2021 08:47 AM Eastern Daylight Time

Today is National Pet Bird Day

BEAK

Contact Details Jamie Baxter +1 775-322-4022 jamie@theimpetusagency.com

September 17, 2021 08:08 AM Eastern Daylight Time

Image

Celebrate National Pet Bird Day on September 17

BEAK

The Bird Enjoyment & Advantage Koalition (BEAK), a concentrated effort to educate on and grow responsible bird ownership, is excited to announce the 3 rd annual National Pet Bird Day, which will take place Friday, September 17, 2021. Pet bird owners are encouraged to share stories, photos and videos of their birds using the hashtag #NationalPetBirdDay, while others can learn more about the joys and benefits of bird ownership. “Birds are amazing companion animals and are actually very connected to their owners,” said Brent Weinmann, BEAK Chairman. “National Pet Bird Day serves as a day to celebrate all the amazing ways pet birds enrich our lives, educate on responsible bird ownership and encourage others to consider adding a feathered family member to their flock.” What is it exactly that bird owners love most about their beloved companions? According to the American Pet Products Association, bird owners say the top benefits are that birds are fun to watch/have in the household, they provide love, companionship, company and affection, and even relieve stress. But there’s more, studies show birds can also increase social interaction, which is very important to mental health and wellbeing, and pets can be instrumental in teaching children empathy and responsibility. Currently, Millennials represent the largest demographic of bird owners with 45 percent of bird owners being Millennials. For those interested in adding a bird to their home, BEAK offers an interactive quiz at www.myrightbird.com where a series of questions help match users with the right bird for their lifestyle. Quiz questions range from time and financial commitments, living arrangements and noise tolerance, to birds’ level of affection and expected lifespan; all key factors for potential bird owners to consider. “We understand that birds like any pet can be a big commitment and through our resources like the quiz, bird locator, species information and avian vet locator we hope to provide new bird owners the information they need to enjoy the happiness and beauty they bring to a home,” said BEAK president, Dean Reyes. Follow @MyRightBird on social media leading up to National Pet Bird Day for live educational demonstrations, giveaways, photo contests and more! To learn more about National Pet Bird Day visit www.nationalpetbirdday.com for a downloadable toolkit and other ways to participate. About BEAKFounded in 2016, the Bird Enjoyment and Advantage Koalition (BEAK) consists of bird product manufacturers, associations and caregivers with shared interests to address the need for increased, responsible bird ownership. BEAK’s mission is to conduct research, identify existing resources, opportunities and challenges, and educate and drive awareness of the benefits of bird ownership through strategic communications, marketing, collaborations and initiatives. www.MyRightBird.com Contact Details Impetus Agency Jamie Baxter +1 775-322-4022 jamie@theimpetusagency.com

September 16, 2021 11:45 AM Pacific Daylight Time

American Kidney Fund to Hold Congressional Briefing on Increasing Kidney Transplants in Communities of Color

American Kidney Fund

The American Kidney Fund (AKF) will hold an online Congressional briefing, Increasing Kidney Transplants in Communities of Color, today from 1-2 p.m. ET at KidneyActionWeek.org. The briefing will explore the reasons people of color are disproportionately affected by kidney failure, often spend longer on the transplant waiting list, have less access to living donor kidney transplants and often experience shorter survival time of transplanted kidneys. AKF is grateful to AstraZeneca for its leadership support of AKF’s health equity programming. Speakers include: Rep. Lisa Blunt Rochester (D-DE), Assistant Whip for House Leadership Eric Dolby, AKF patient Ambassador from Raleigh, N.C. Nicole Jefferson, AKF patient Ambassador from Dallas J. Keith Melancon, M.D., Chief of the GW Transplant Institute and professor of surgery at The George Washington University Hospital Ken Sutha, M.D., Instructor of Pediatric Nephrology at Stanford University School of Medicine and AKF Ambassador from Palo Alto, Calif. And moderator Frances Ashe Goins, Former Deputy Director for the U.S. Department of Health and Human Services Office on Women’s Health; adjunct professor at the University of South Carolina and member, AKF National Board of Trustees “The most effective treatment for kidney failure is a kidney transplant; however, people of color—who are already impacted by disproportionate rates of kidney failure—often struggle to access this lifesaving procedure,” said LaVarne A. Burton, AKF President and CEO. “Persisting disparities have led to worse health outcomes for communities of color, and we are calling on members of Congress to ensure equitable access to kidney transplantation for all patients who need one.” One important strategy to confront health disparities in transplant is increasing living organ donations, especially by and for people of color. In 2020, 64% of the 5,234 living donor kidney transplants performed in the United States went to white recipients. Just 11% went to Black recipients and 16% went to Hispanic recipients. Kidneys from living organ donors last 15-20 years on average, while kidneys from deceased donors last an average of 10-15 years. Existing policy barriers discourage many would-be donors from making living organ donations. AKF continues to spearhead legislation at the state and federal level to increase living organ donor protections to make more kidneys available for transplantation, and the 16,000 patient Ambassadors in AKF’s Advocacy Network have been an important part of that work. The briefing is part of AKF’s Kidney Action Week, a week-long schedule of virtual events focusing on kidney disease prevention, management, nutrition, dialysis and transplantation, that is running from Sept. 13-17. Health disparities are an overarching theme throughout the week. Kidney Action Week is made possible by the generosity of sponsors Boehringer Ingelheim/Lilly, Otsuka America Pharmaceutical, Inc. and US Renal Care. AKF is also grateful to session sponsors AstraZeneca, Alexion Pharmaceuticals, GSK, Horizon Therapeutics plc, Natera, Sanofi Genzyme, Travere and Vertex Pharmaceuticals. ### About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck Work: +1 202-470-1797 Mobile: +1 978-390-1394 11921 Rockville Pike Suite 300 Rockville, MD 20852 AKF@jpa.com Company Website http://www.kidneyfund.org/

September 15, 2021 08:00 AM Eastern Daylight Time

£2.5m Charity Appeal launched by Liverpool legend for new neonatal ICU

Alder Hey

Jamie Carragher is backing a new fundraising appeal for a brand new, state of art Surgical Neonatal Intensive Care Unit (NICU) at Alder Hey Children’s NHS Foundation Trust in Liverpool, UK. Jamie, who was treated at Alder Hey’s neonatal ward for the first six weeks of his life, is launching the appeal to raise £2.5m for the new Surgical NICU on behalf of Alder Hey Children’s Charity. The new Surgical NICU is a joint project between Alder Hey and Liverpool Women’s NHS Foundation Trust as the Liverpool Neonatal Partnership. Subject to planning permission, the new unit will result in a further 22 neonatal cots for Liverpool and will feature 18 individual family rooms where parents can be alongside their poorly new-borns whilst they’re receiving expert care. The unit will address a shared concern between Liverpool Women’s and Alder Hey that babies who need specialist surgery currently have to be transferred to Alder Hey to get the specialist surgical care they need and are then transferred back to Liverpool Women’s Hospital to continue their specialist neonatal care. The planned facility will cost £16.5m to build with the Charity Appeal aiming to contribute £2.5m. Charity funding will provide ‘over and above’ enhancements and equipment for both the clinical space and family areas, elevating it from a facility that provides families with a safe and secure environment for them and their new-borns, to a truly world-class facility that wraps-around families with the most vulnerable babies in the region. Jamie Carragher said: “My family and I will forever be grateful to Alder Hey after they cared for me as a baby. The plan to build a new neonatal unit sounds like a fantastic idea. It will help keep families together at such a worrying time and provide lifesaving treatment. I am proud to support this appeal and it is something we can all get behind.” Fiona Ashcroft, CEO of Alder Hey Children’s Charity said: “Jamie has been a supporter of the work of the hospital for many years and is a brilliant Charity Champion for Alder Hey – we were delighted this Liverpool Legend accepted our suggestion to head the Appeal to help us spread the word in the region as well across the country. We can’t wait to see the build start; this unit is going to be world leading!” Specialist neonatal staff from Liverpool Women’s Hospital will plan to work alongside Alder Hey at the new NICU ensuring that poorly babies are transferred between the two hospitals as little as possible. Central to the new unit will be the use of new innovative technology. This will continue to include Telehealth Medicine Robots currently being used which allow clinicians to monitor and see babies remotely. There are further technologies being worked through currently to support the vision of a silent NICU including Neonatal Tracking; a wearable device worn around a parents wrist which send signals to receivers around the hospital and allow staff to know where the parent is in case of an emergency and also virtual monitoring of babies, allowing doctors and nurses to have access to have constant sight on the babies and their vital signs, whilst still providing the family with the safety and privacy of a cubicle. Planning permission is to be submitted at the end of September 2021. You can donate towards the Appeal at www.alderheycharity.org/surgical-neonatal-appeal Editor’s notes For more information about Alder Hey please contact: media@alderhey.nhs.uk About Alder Hey Children’s Charity Alder Hey Children’s Hospital treats over 330,000 children every year – that’s more than 900 children each and every day, more than any other children’s hospital in the UK. Alder Hey Children’s Charity supports the work of Alder Hey Children’s NHS Foundation Trust by raising much needed funds that are spent directly on initiatives in the hospital to benefit patients. Without the support of charitable donations, many of the outstanding facilities and innovations at Alder Hey could not be achieved. Alder Hey Children’s Charity has raised over £56m since April 2013 for a range of life-saving medical equipment and facilities that are making a real difference to families every day. Further Information The new NICU is subject to planning permission approval. In 2019/20, 147 babies were transferred between the two hospitals with some transferred multiple times. Every transfer carries a risk to these babies at the most vulnerable time in their lives and can often lead to separation from parents and/or multiple birth siblings. The new Surgical NICU will offer, for the first time, an integrated clinical pathway between Alder Hey and Liverpool Women’s Hospital which will enhance the clinical care model for babies requiring surgery in the new-born period. Specialist neonatal staff from Liverpool Women’s Hospital will work alongside Alder Hey at the new NICU ensuring that babies do not need to be transferred back and forth between the two hospitals. The new facility will significantly reduce the number of transfers needed as well as improve the care for all babies requiring neonatal surgery, ensuring all developmental and care needs are met. It will also bring parents and their babies together in a private, comfortable setting so they can bond as a family. This means parents can be by their baby’s side every step of the way. Contact Details Phil McNamara +44 151 293 3502 media@alderhey.nhs.uk Company Website https://www.alderhey.nhs.uk/

September 15, 2021 03:01 AM Eastern Daylight Time

Image

LIVERPOOL JOHN LENNON AIRPORT GETS ‘STATE OF THE ART’ COVID PCR TESTING LABORATORY

Test Assurance Group (TAG), Salutaris People, Source BioScience and Liverpool John Lennon Airport

TEST ASSURANCE GROUP (TAG) AND SALUTARIS PEOPLE PARTNERS WITH SOURCE BIOSCIENCE TO PROVIDE 3 HOUR RAPID PCR TESTING SERVICES FOR JOHN LENNON AIRPORT AIRLINE PASSENGERS ON SITE LAB WILL ERADICATE ‘UNCLEARS’ & ‘LOST TEST’ RESULTS Leading British healthcare and testing company Salutaris People - which operates the rapid PCR testing services for airline passengers at Liverpool John Lennon Airport, in partnership with Test Assurance Group Ltd (TAG(Official Covid-19 testing partner to Liverpool John Lennon Airport)- has today unveiled a brand new COVID testing laboratory at Liverpool John Lennon Airport. The state-of-the-art facility is in partnership with Source BioScience - a leading international provider of laboratory services to clients in the pharmaceutical industry, healthcare, clinical, life science research and biopharma industries - and Salutaris People in partnership with Test Assurance Group Ltd (TAG) are providing COVID and PCR testing at Liverpool John Lennon airport. The new laboratory has been designed to perform 500 tests per day but can easily be increased in scale to facilitate 1000 tests and beyond if required. Source BioScience are Accredited to ISO 15189: 2012 standards and is also a DHSC listed provider of COVID-19 testing. The service provided by TAG, Salutaris People,and Source BioScience enables airline passengers at Liverpool John Lennon Airport and those flying from other UK airports with a Rapid Fit to Fly testing service with a turnaround time of 3 hours, alongside a Standard 24 hour Fit to Fly testing service. Samples are also collected on site at Liverpool and processed at Source BioScience’s main laboratory in Nottingham enabling Day 2, Day 8, Test to Release and a diagnostic PCR COVID testing service for customers. Cliff Kirby Board Director of Test Assurance Group said: "We are incredibly proud to be working in partnership with Liverpool John Lennon Airport to support their testing needs. As a business located in the Liverpool City Region it is very important to TAG to ensure the service offered is best in class. Throughout the course of 2021 we have put the passenger first whenever there has been a change in legislation or entry requirements for travel has changed. In line with this it is brilliant for all concerned that Source BioScience have dedicated a facility to support the vision laid out between TAG and Liverpool John Lennon Airport. As we all start to accept and learn to live with COVID-19 we hope that our approach will make a real difference to those passengers who choose to fly from Liverpool John Lennon Airport." Ben Paglia MD of Akea Life, the clinical testing partner to Salutaris People said; “We are pleased to be working in partnership with Source BioScience to provide brand new state of the art facilities on site at Liverpool John Lennon Airport and to offer our customers the best-in-class when it comes to rapid PCR testing services. For airline passengers using Liverpool John Lennon airport, or any other UK airport for that matter, they can book a test with confidence, knowing their COVID test will be administered by trained healthcare staff and then processed on site within our laboratory, with results back in 3 hours or 24 hours depending on the service chosen. We offer a seamless and simple user journey experience for the customer, making this part of the travel process as simple and painless as possible from a trusted healthcare provider. More importantly with our lab facilities on site this eradicates test results going missing in the postal system and the huge amount of ‘Unclear’ test results that have originated from self-administered test kits provided by major airlines and travel operators as part of their testing regimes. This has caused a huge amount of disruption with passengers paying twice for testing kits and a huge amount of disruption to air travel and holiday plans. ‘Unclears’ and ‘lost test results’ continue to pose a major issue to airline passengers.” Salutaris People are committed to providing the best possible testing services to its customers from Liverpool John Lennon Airport to make the testing experience seamless, simple and easy to use. It has made a substantial investment into the onsite laboratory facilities at Liverpool John Lennon airport as European and International air travel strives to return to full flight schedules. Commenting on the new facilities at Liverpool John Lennon airport, Commercial Director Lucy O’Shaughnessy, said; “We are delighted to be the first airport in the UK to have such a unique facility and service. Liverpool John Lennon Airport can now provide our valued airline passengers with a state-of-the-art COVID testing facility on site here at the airport as we start to resume our flight schedules and have more passengers flying again. The airport continually strives to offer the best possible service for our customers at all times. Working in partnership with Test Assurance Group (TAG) / Salutaris People and Source BioScience enables us to offer a convenient and efficient PCR testing service operated by trusted healthcare providers.” Liverpool John Lennon Airport is one of the few airports in the UK to have such a dedicated facility. It is operated by four laboratory staff including a shift supervisor and has 8 PCR analysers on site, a Bio Molecular Systems liquid handler and a thermal cycler to offer a rapid real-time qualitative PCR method for the detection of SARS-CoV-2. Nick Bills Healthcare Director for Source BioScience said; “Source BioScience have worked together with EMS Mobile Healthcare to design and build a state-of-the-art mobile COVID testing laboratory for Salutaris People at Liverpool Airport. This laboratory will allow Salutaris People to offer the best-in-class testing services to airline passengers flying from Liverpool John Lennon airport. Source BioScience is a leading international provider of laboratory services to clients in the pharmaceutical industry, healthcare, clinical, life science research and biopharma industries and our focus is on improving patient diagnosis, management and care.” Both Test Assurance Group and Salutaris People are DHSC listed COVID-19 test providers. Salutaris People also offer a testing suite at Wilmslow which is minutes from Manchester Airport. The TAG / Salutaris partnership nables them to offer their service to all passengers flying from either Liverpool John Lennon Airport or Manchester Airport, as well as airline passengers who live in Liverpool, North Wales, Manchester and Cheshire who may be flying from other UK airports to their holiday destinations. For more information on Salutaris People and to book a test, visit: www.salutarispeople.com For more information on Test Assurance Group and book a test visit: www.testassurancegroup.com/bookatest For more information on Salutaris airport testing, visit: www.salutarispeople.com/airport-testing/ For more information on Source BioScience please contact https://www.sourcebioscience.com ENDS For further information on Salutaris People, Akea Life, Test Assurance Group and Source BioScience Please contact Gerard Franklin - Head Of PR & Communications M: 07791 039636 e: gerard@i5media.co.uk NOTES TO EDITORS TEST ASSURANCE GROUP (TAG) TAG was formed at the end of Q1 2020 to address the inevitable need to provide end to end testing solutions supporting the national effort to help navigate a route through the COVid-19 pandemic. TAG take the view that the post pandemic World will be quite different to that of early 2020. To that end TAG take a very different approach and make best use of process and technology to build and deliver end to end testing solutions that deliver efficiencies to the market and enable an easier transition to a post COVID-19 market. The Core team at TAG bring with them over 200 years of business experience across all sectors from medical, legal, group ownership, and technology. However, TAG are very much a business that believe in partnership and work closely with the team at Liverpool John Lennon Airport and Salutaris People. Outside of the partnership with Liverpool John Lennon Airport TAG are working with a range of community partners to bring forward Covid-19 testing solutions to the market to support a much wider community footprint. www.testassurancegroup.com SALUTARIS PEOPLE Salutaris People was formed in 2020 by healthcare entrepreneurs and disruptors Ross Tomkins CEO (Therapy Direct, Normedica) and Ben Paglia CEO (Akea Life) who wanted to combine their innovative healthcare businesses to develop a trusted healthcare brand. Its purpose was to fight the Coronavirus pandemic and become a trusted provider of Covid related medical services. Ross Tompkins and Ben Paglia decided to combine their expertise from three well established medical businesses with 30 years of healthcare experience to form the Salutaris subsidiary. The company provides a range of medical services including, PCR Covid 19 testing for businesses, private individuals and outbound airline passengers. It also supplies rapid antigen and rapid antibody testing for UK businesses and remote telemedicine services for business and the general public. Salutaris People is also one of the UK’s most trusted suppliers of high-grade PPE, pharmaceuticals and medical supplies to private businesses, primary care trusts, the public sector and Governments. It draws upon on the extensive background and expertise in medical services and healthcare derived from these companies www.salutarispeople.com AKEA LIFE – Clinical Testing Partner To Salutaris People AKEA LIFE is a CQC registered 5-star private GP medical business, providing the UK’s first fully private concierge medical service of private doctors, health care professionals and nurses. The practice also retains a Covid 19 Consultant Virologist to advise on all Covid 19 related matters. Its clients have ranged from football clubs such as Liverpool Football club, Aston Villa, Wolverhampton Wanderers, IAC Automotive, Lift Financial and Bentley Manchester. It has also provided private Covid 19 testing for several TV and film companies including a number of Hollywood actors filming on location in the UK https://akealife.co.uk AKEA LIFE - Consultant Virologist - Dr Brendan Payne Dr Brendan Payne is an honorary consultant physician in infectious diseases at the Royal Victoria Infirmary - Newcastle Upon Tyne. Dr Brendan Payne holds CCTs in both infectious diseases and virology and works jointly across both departments at the Newcastle Hospitals. He has particular interests in viral infections, especially in immunocompromised hosts, and is also the medical lead for the regional Chronic Fatigue Syndrome (CFS) service. Dr Payne is an honorary clinical senior lecturer at Newcastle University, where he is a Principal Investigator in the Wellcome Centre for Mitochondrial Research. His main research interests are focussed on HIV and ageing. He is also involved in clinical and diagnostic research studies for the Newcastle Hospitals. These include clinical trials in HIV, and more recently COVID-19. He is senior tutor for medical students intercalating into the MRes programme. Special interests • Complex HIV (particularly neurological, metabolic complications, and anti-retroviral resistance) • Infection in the non-HIV immunocompromised patient • Viral infectious diseases • Diagnostics of viral infections • Chronic fatigue syndrome • Clinical research SOURCE BIOSCIENCE Source BioScience is a leading international provider of laboratory services to clients in the pharmaceutical industry, healthcare, clinical, life science research and biopharma industries and our focus is on improving patient diagnosis, management and care. Source BioScience are Accredited to ISO 15189: 2012 standards and also one a DHSC listed provider of COVID-19 testing. Professor William L. Irving, Professor and Honorary Consultant in Virology is part of the Source BioScience Scientific Advisory Board, see full profile here https://www.sourcebioscience.com/scientific-advisory-board/professor-william-l-irving/ Proud winners of the Medilink Midlands Business Awards 2021 ‘Delivery Innovation In To Health and Care’ Source BioScience services include: Healthcare Diagnostics – histopathology and clinical diagnostic services for the NHS and private healthcare providers across the UK and Ireland. Genomics – Sanger and Next Generation sequencing services for pharmaceutical and biotech industries, academia, CRO and other research groups in the UK, Europe and the US Stability Storage – controlled environmental storage and shelf life testing services and stability storage equipment for pharmaceutical and biotechnology industry, contract manufacturers and analytical testing companies in the UK, Europe and the US Infectious Disease Testing – since May 2020, COVID-19 Antigen RT-PCR testing services to the NHS, private healthcare providers and private industry. More details can be found here: www.sourcebioscience.com MEDIA NOTICE Ben Paglia MD Akea Life & Cliff Kirby Test Assurance Group are available for media interviews B Roll footage shot at Liverpool John Lennon Airport Interviews and footage of the laboratory Source BioScience laboratory images interior /exterior and company logos Are all available to download here from WE TRANSFER https://we.tl/t-8gYR96awZA Contact Details Gerard Franklin +44 7791 039636 gerard@i5media.co.uk Company Website https://testassurancegroup.com/

September 15, 2021 03:01 AM Eastern Daylight Time

Image

The 2021 American Thoracic Society Virtual Event

Convey Services

In 2021 the American Thoracic Society hosted their annual conference as a virtual event. The ATS Virtual Conference provided both attendees and exhibitors with a virtual experience that would closely replicate the in-person environment. The ATS International Conference attracts pulmonary, critical care, and sleep professionals, from those in the earliest stages of their careers to those whose research or strides in clinical care has gained them international recognition. Each year, nearly 14,000 of these professionals choose to attend, present, and learn about the latest advances, meet with colleagues from around the world, and create new collaborations and connections. It is truly where today’s science meets tomorrow’s care. Download the case study for free at: Case Study in Virtual & Hybrid Events for Medical Organizations — The story of ATS 2021. “The MCI Group was tapped to be the event management company for the ATS virtual event, said Carolyn Bradfield, CEO of Cloud Conventions. “MCI is a global engagement and marketing agency that creates human-centric touchpoints to unleash the power of people to deliver innovation and growth. Cloud Conventions was selected as the virtual technology platform to manage the ATS virtual event. Our solutions is a sophisticated enterprise platform that manages everything needed to execute a flawless virtual event, tradeshow or conference.” ATS Virtual Conference Goal The virtual conference was designed around three main elements to meet the goal: • Presentations & Sessions • CME/MOC Education • The Industry Solution Center for sponsors Attendees at the ATS Virtual Conference engaged through networking events featuring experts from the medical industry, attendee-to-exhibitor real-time chat, online discussion forums and “ Community™ ” featuring searchable attendee directories, profile cards for each attendee and instant messaging between attendees. The live portion of the virtual conference was held over a five-day period, and on-demand content was made available for ninety days. Click here to download: Case Study in Virtual & Hybrid Events for Medical Organizations — The story of ATS 2021 About Cloud Conventions Cloud Conventions from Convey Services is Cloud Conventions is an enterprise virtual/hybrid event management platform that redefines the exhibitor and attendee experience to allow companies to provide easy access to in-depth product information, showcase their brands with graphics and videos, create calls to action and generate immediate sales leads. Used around the world for large managed events and smaller self-directed meetings, conferences and corporate kickoffs, Cloud Conventions automates exhibitors and virtual booths, continuing education, speaker sessions and reminders, invitations and email communication, while at the same time producing detailed analytics on attendee, session and exhibitor activity. Cloud Conventions supports multiple languages and currencies, internal, external and single-sign on registration, and supports all conferencing carriers and platforms. Trade Associations and event managers can explore all of the Cloud Conventions solutions by visiting https://cloudconventions.com or contacting info@cloudconventions.com or call 888-975-1382. Cloud Conventions™, Cloud Conventions Enterprise Event Network™, Community™, SafetyNet™, Cloud Kickoffs™, Conduct™, One-Touch Email Share™, Hub & Spoke™, 360° Virtual Exhibit Hall & Lobby Experience™ and ListLock™ are trademarks of Convey Services LLC Contact Details Bruce Ahern +1 770-580-0810 bahern@conveyservices.com Company Website https://cloudconventions.com

September 14, 2021 04:42 PM Eastern Daylight Time